Boehringer Ingelheim preps FDA submission with new data in rare pediatric lung disease
Ofev was one of Boehringer Ingelheim’s top sellers in the first half of this year, raking in a whopping $1.48 billion. Now the German pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
